
Patients at baseline
n = 4,247
n = 14: no informed consent
Patients at baseline
with informed consent
n = 4,233
Effectiveness analysis
Safety analysis
n = 916: pre-treatment group not assigned or previously received fingolimod
n = 43: pre-treatment group not assigned
Patients at baseline receiving fingolimod for the first time with informed consent
n = 3,317
Patients at baseline with informed consent
n = 4,190
n = 20: baseline visit data not available
n = 26: baseline visit data not available
Patients receiving fingolimod for the first time, with informed consent and a baseline visit date
n = 3,297
Patients with informed consent and a baseline visit date
n = 4,164
n = 760: 12-month visit data not available
n = 898: 12-month visit data not available
Patients receiving fingolimod for the first time, with informed consent, baseline and 12-month visit date
n = 2,537
Patients with informed consent, baseline and 12-month visit date
n = 3,266
n = 540: 24-month visit data not available
n = 670: 24-month visit data not available
Patients receiving fingolimod for the first time, with informed consent, baseline, 12- and 24-month visit dates
n = 1,997
Patients with informed consent, baseline, 12- and 24-month visit dates
n = 2,596
n = 479: 36-month visit data not available
n = 582: 36-month visit data not available
Patients receiving fingolimod for the first time, with informed consent, baseline, 12-, 24- and 36-month visit dates
n = 1,518
Patients with informed consent, baseline, 12-, 24- and 36-month visit dates
n = 2,014